Atlantic Healthcare (AgeTech UK) Biomed
Gastrointestinal diseases, owns the worldwide rights to renzapride, a molecule, work also on orphan diseases. Currently developing differentiated, first-in-class treatments that leverage alicaforsen, an antisense therapeutic agent with a novel target for validated mechanism of action and the potential to treat multiple inflammatory GI diseases.
Headquarters:
United Kingdom
Employee Number:
N/A
Founded Date:
N/A
Investment Stage:
N/A
Technology:
AgeTech Companies
Investor Type:
N/A
Number Of Exists:
N/A
Industry:
UK AgeTech 2020
Funding Status:
N/A